Boston Scientific to Acquire Penumbra for $14.5 Billion, Eyeing Neurovascular Expansion

Boston Scientific announced its largest acquisition in two decades, agreeing to buy Penumbra for approximately $14.5 billion. The deal, disclosed January 15, 2026, aims to significantly expand its cardiovascular and neurovascular market presence amid ongoing sector consolidation. The definitive agreement values Penumbra at an estimated $374 per share. This transaction marks Boston Scientific's most substantial acquisition in the past 20 years, underscoring its aggressive growth strategy. Why this matters now: This acquisition is poised to reshape competition within the medical technology landscape, particularly in the high-growth neurovascular segment. It signals Boston Scientific's determined push for market leadership and innovation. Following the announcement, Penumbra's stock surged, reflecting the attractive premium offered. Conversely, Boston Scientific shares saw a decline, a typical market reaction to large capital outlays by acquirers. The acquisition is designed to fortify Boston Scientific's heart device portfolio. It also strategically re-enters the neurovascular segment, leveraging Penumbra's specialization in devices for stroke and related conditions. Analysts have offered generally positive long-term assessments of the deal's strategic merits. Stifel praised the acquisition, while Morgan Stanley suggested Boston Scientific's stock may be undervalued post-announcement. The transaction remains subject to customary closing conditions and critical regulatory approvals. Investors will closely monitor the integration process and its financial impact on Boston Scientific. This transformative acquisition highlights Boston Scientific's commitment to strategic expansion and market leadership. Its successful integration could drive significant innovation and influence future patient care standards.